Condition: Coronary Artery Disease · Drug Eluting Balloon · Drug Eluting Stent · Sponsor: Translumina GmbH
The main objective of the SPARX trial is to compare paclitaxel-coated balloons to with contemporary DES in complex and small coronary artery lesions in patients with NSTEACS or CCS; the co-primary objective is to compare two different paclitaxel-coated balloons, Protégé and Agent, with each other.
This description comes directly from the study's public registry record.
Dr Brijesh Mishra, PhD · +919654596737 · drbrijeshmishra@translumina.in
Deepanshi Thakur, MSc · deepanshithakur@translumina.in
Always discuss trial participation with your own doctor first.
| Luzerner Kantonsspital Spitalstrasse, 6000 Luzern 16, Switzerland | Lucerne, Canton of Lucerne, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07397845